Abstract
Background: There are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications. Methods: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women. Results: Topical use of timolol alone or timolol in combination with other antiglaucoma medications does not influence pregnancy or fetal/neonatal outcomes. Conclusion: Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.
Original language | English |
---|---|
Pages (from-to) | 3-11 |
Number of pages | 9 |
Journal | Current Drug Safety |
Volume | 13 |
Issue number | 1 |
DOIs | |
Publication status | Published - Mar 1 2018 |
Keywords
- Congenital anomalies
- Drugs
- Glaucoma
- Pregnancy
- Prenatal diagnosis
- Teratology Information Service (TIS)
ASJC Scopus subject areas
- Toxicology
- Pharmacology
- Pharmacology (medical)